Edinburgh EH9 3FD UK 8 Equal contributions 9 Corresponding authors: Adrian Bird, a.bird@ed.ac.uk; Bartlomiej Waclaw, bwaclaw@ph.ed.ac.uk; Patterns of gene expression are primarily determined by proteins that locally enhance or repress transcription. While many transcription factors target a restricted number of genes, others appear to modulate transcription levels globally. An example is MeCP2, an abundant methylated-DNA binding protein that is mutated in the neurological disorder Rett Syndrome. Despite much research, the molecular mechanism by which MeCP2 regulates gene expression is not fully resolved. Here we integrate quantitative, multi-dimensional experimental analysis and mathematical modelling to show that MeCP2 is a novel type of global transcriptional regulator whose binding to DNA creates "slow sites" in gene bodies. Waves of slowed-down RNA polymerase II formed behind these sites travel backward and indirectly affect initiation, reminiscent of defectinduced shock waves in non-equilibrium physics transport models. This mechanism differs from conventional gene regulation mechanisms, which often involve direct modulation of transcription initiation. Our findings uncover a genome-wide function of DNA methylation that may account for the reversibility of Rett syndrome in mice. Moreover, our combined theoretical and experimental approach provides a general method for understanding how global gene expression patterns are choreographed.
Here we set out to resolve the mechanism of MeCP2-dependent transcriptional regulation.
Because MeCP2 binding sites occur in the vast majority of genes, we reasoned that most are likely to be influenced to some extent by its presence. To confront the technical and analytical challenges posed by modest changes in expression of large numbers of genes, we adopted a quantitative approach that combined deep, high quality datasets obtained from a uniform population of Lund Human Mesencephalic (LUHMES)-derived human dopaminergic neurons (18) with computational modelling. We created a spectrum of LUHMES cell lines expressing distinct levels of MeCP2. Using transposase-accessible chromatin sequencing (ATAC-seq) and chromatin immunoprecipitation (ChIP-seq) together with mathematical modelling, we detected a robust footprint of MeCP2 binding to mCG and mCA in vivo and determined the amount of MeCP2 bound to DNA. Quantification of mRNA abundance by RNA-seq revealed a relationship between changes in transcription and the density of mCG on gene bodies. To explain this observation, we proposed and tested several distinct mechanistic models. The only model consistent with our experimental results is one in which MeCP2 leads to slowing down of RNA polymerase II progression through a transcription unit. Importantly, mutant
MeCP2 that is unable to bind NCoR fails to repress efficiently, suggesting that repression depends upon this interaction.
Results
Global changes in transcription correlate with MeCP2 expression level. We created progenitor cell lines capable of differentiation to a uniform population of human neurons (Fig. S1A-C) that expressed seven widely different levels of MeCP2, including knock-out (KO), wildtype (WT) and 11-fold over-expression (11x) (Figs. 1A,B and S1D; see Table S1 ). All lines differentiated into neurons with similar kinetics, expressed neuronal markers (Fig. S1E ), and had identical global levels of DNA methylation (~3.7% of all cytosines were methylated) ( Fig.   S2A ). To determine effects of MeCP2 levels on transcription, we performed RNA-seq on all seven cell lines. Most of the ∼ 17000 expressed genes responded to MeCP2 abundance, but changes were small (Fig. S3A ). Based on known affinity of MeCP2 for methylated CG (mCG), we expected MeCP2 to affect genes depending on their mCG content. We therefore quantified DNA methylation for all genes in WT neurons using whole-genome bisulfite sequencing (TABseq) ( Fig. S2B,C) . In order to detect small changes in expression which might otherwise be obscured by other regulatory mechanisms and statistical noise, expressed genes were binned according to methylation density, considering gene bodies and promoters separately.
The average change in expression versus appropriate controls (Log2FC) showed a strong relationship to mCG density ( '() ) in gene bodies (Fig. 1C) . The effect was the strongest for '() =0.8-4.0 mCG per 100bp which includes the vast majority of genes ( Fig. S3B ). Moreover, the maximum slope of the Log2FC versus '() in gene bodies (Fig. 1C , black lines) was strikingly proportional to MeCP2 levels ( Fig. 1D ). In contrast, plots of Log2FC versus '() in promoter regions showed a slope close to zero, indicating minimal dependence on promoter methylation ( Fig. S3C ). No clear dependence on MeCP2 level was observed for Log2FC versus total gene body mCG or mCG mean (Figs. S3D, E). These results indicated that the gene-body mCG density is the strongest predictor of MeCP2-dependent transcriptional changes. To test for a causal relationship, we transfected cells with two versions (methylated or unmethylated gene body) of a luciferase reporter gene with a methylation-free promoter in the presence of wildtype or the DNA binding mutant MeCP2[R111G] ( Fig. S4 ). We observed a two-fold repression of methylated versus unmethylated luciferase gene body in the presence of WT MeCP2 compared to either no MeCP2 or mutant MeCP2 (Figs. 1E).
MeCP2 binds predominantly methylated CG genome-wide. To map the binding of MeCP2
in human neurons, we performed MeCP2 ChIP-seq for KO, WT, OE 4x and OE 11x, and simultaneously developed a computer model that simulates the ChIP-seq procedure and MeCP2 binding in vivo ( Fig. 2A ). As expected, ChIP enrichment was proportional to the level of MeCP2 in each cell line ( Fig. S5A -C) and showed a strong peak centred at mCGs in To derive an independent measure of absolute MeCP2 density on the DNA and to detect its molecular footprint with high resolution, we performed ATAC-seq (19) in which transposase Tn5 cuts exposed DNA to reveal DNA accessibility within chromatin ( Fig. 2A ). In agreement with ChIP-seq, ATAC-seq Tn5 insertion profiles (Figs. 2D) showed a graded depletion of insertion sites centered around mCG in WT, OE 4x and OE 11x neurons, whose amplitude was proportional to MeCP2 concentration ( Fig. 2E ) and therefore represents a "molecular footprint" of MeCP2 binding in vivo. An equivalent but weaker profile was seen at mCA, but was absent at non-methylated CG and GT and TA dinucleotides (Fig. S6 ). The size and amplitude of the footprint agrees well with a computer model of ATAC-seq and MeCP2 binding ( Fig. 2D , black lines) and previous in vitro data (20, 21) , confirming that MeCP2 occupies 11bp of DNA in living cells. The model revealed that only 6.3% of mCG sites are actually occupied by MeCP2 in OE 11x neurons, falling to less than 1% occupancy in WT ( Fig. 2E ), perhaps due in part to occlusion by nucleosomes. Excellent agreement between the models and ATAC-seq and ChIP-seq data allows us to predict MeCP2 occupancy from mCG density and MeCP2 level in each cell line.
MeCP2 does not regulate transcription via condensation of chromatin or premature
termination. To interpret these results mechanistically, we considered mathematical models based on a commonly accepted paradigm for gene expression ( Fig. S7A) (22) . In the first class of models named Condensation models ( Fig. 3A) , MeCP2 affects the rate of transcription initiation via changes in chromatin structure. The possibility that MeCP2 affects the initiation rate by binding to promoters was rejected because it would imply a stronger correlation between gene expression and '() in promoters than in gene bodies, contrary to our observations ( Fig. S3C ). MeCP2 could hypothetically affect the fraction of cells with specific genes in the ON state via some long-distance mechanism involving binding to gene bodies and changing the degree of chromatin openness near promoters. However, mapping chromatin accessibility using ATAC-seq showed that while there is a correlation between MeCP2 and accessibility ( Fig. 3B ), it cannot account for the observed Log2FC in gene expression ( Fig. 3C ).
We next considered potential effects of MeCP2 on the elongation phase of transcription. The Detachment Model posits that MeCP2 causes transcription to prematurely abort ( Fig. 3D ).
Since the probability of termination increases with each blocking site, under this model the (23)). Inspired by non-equilibrium statistical mechanics of one-dimensional transport models (24, 25) , we expect a nonequilibrium phase transition from a low-density to a maximal-current (congested) phase as the initiation rate or the density of obstacles increase beyond a certain critical point. Indeed, all curves in Fig. 4B have a characteristic shape: a linear relationship ≈ for small , followed by saturation at high initiation rates. Saturation occurs due to congestion as polymerases queue upstream of obstacles (SI Videos 1,2). However, even in the non-saturated regime of intermediate , excluded-volume interactions between polymerases that have been slowed down by an obstacle cause a density shock wave that propagates backwards ( Fig. 4C ). A small increase in the density of polymerases near the promoter decreases the rate of Pol II binding to the TSS. Thus, even though MeCP2 does not directly affect Pol II initiation, it does so indirectly by shock waves that form behind MeCP2-induced obstacles in gene bodies ( Fig.   4D ). To test the model against RNA-seq data, we estimated average initiation rates for genes with similar mCG densities by fitting the model to Log2FC(OE 11x/OE ctr) versus '() ( Fig.   4E left, see also SI Section 10.2). We then used the model to predict Log2FC data for the In summary, a close alliance between mathematical modelling and molecular biology has allowed us to discriminate molecular mechanisms underlying the relatively subtle global effects of MeCP2 on global gene expression. The proposed mechanism relies on MeCP2-NCoR interaction that slows down the progression of Pol II during transcription elongation. A candidate mediator of this effect is histone modification, in particular histone deacetylation.
The NCoR1 and NCoR2 complexes both recruit histone deacetylases whose action would increase the affinity between DNA and nucleosomes and thus inhibit transcription (26) . In fact, cell transfection assays using MeCP2 and methylated reporters have demonstrated that repression depends upon histone deacetylase activity (11, 12) .
To explain the dramatic reversibility of Rett syndrome in animal models (29) we propose that, in the absence of MeCP2, DNA methylation patterns are unaffected, allowing the re-expressed wildtype protein to bind within gene bodies and commence normal modulation of transcriptional elongation. The Congestion Model may apply to proteins other than MeCP2.
For example, other chromatin-binding factors that bind short (and thus abundant) motifs, including other methyl-binding proteins, may modulate gene expression by a similar mechanism.
Materials and methods
Cell lines. The procedure for culture and differentiation of the LUHMES cell line was previously described (18) . To create two independent MECP2 knock-out lines, we used CRISPR-mediated gene disruption (30) . To generate MeCP2 knock-downs, several shRNAs against MeCP2 were designed using Sigma-Aldrich Mission shRNA online software. Two shRNAs were chosen and cloned into pLKO.1 vector including scrambled shRNA as a control and lentiviruses were created (Table S2) Methylome of wildtype LUHMES-derived neurons at day 9 was obtained by TAB-seq according to the published protocol (31) . RNA-seq library was performed according to manufacturer protocol for ScriptSeq Complete Gold kit (Human/Mouse/Rat). Total RNA was isolated from all generated cell lines (Table S1) at day 9 of differentiation using either the RNeasy Mini kit or the AllPrep DNA/RNA Mini kit (Qiagen). ATAC-seq in four cell lines (KO, WT, OE 4x and OE 11x, see Table S1 ) was performed as in (32) . See SI Methods Section 2 for details.
MeCP2 ChIP-seq was performed using LUHMES-derived neurons at day 9 of differentiation with four levels of MeCP2: KO, WT, OE 4x and OE 11x (see Table S1 ). Cells were crosslinked with 1% of Formaldehyde (Sigma) in the medium for 10 min at RT and quenched with 2. Data processing of raw reads from Illumina sequencing. All reads were quality-controlled, trimmed to remove adapters (Trimmomatic) (33) , and duplicated reads, and mapped to the human hg19 reference genome. Bismark (34) was used to extract cytosine methylation from TAB-seq. Total methylation (total mCG) in a gene was calculated as the total number of methylated CG dinucleotides. mCG density was calculated by dividing total methylation by the length of the corresponding region (gene body or promoter). mCG mean was defined as the total mCG divided by the number of all CG dinucleotides and multiplied by 100. See SI Methods Section 3 for details.
ChIP-seq enrichment profiles. We first obtain accumulated counts (the number of reads) < = that overlap with -th basepair to the right ( > 0) or left ( < 0) from feature ( =mCG, mCA, …). We then calculate enrichment profiles as We consider a particular C to be methylated if it is methylated in 100% of the reads, and the coverage is at least 5. We consider a C to be unmethylated if it does not show up in any of the ChIP-seq reads as methylated. See SI Methods Section 4 for details.
Computer model of ChIP-seq. We assume that MeCP2 occupies methylated cytosines with probability times the probability of binding to a particular motif (SI Section 5). Binding probabilities for different motifs are based on known binding affinities (35) and relative binding strengths (15) . To create simulated ChIP fragments, we assume that if a DNA fragment contains at least one MeCP2 bound to it, it will be present in the simulated ChIP-seq.
Fragments that do not contain any MeCP2 may still be present in the ChIP-seq data with probability ]^ which accounts for "background" reads in ChIP-seq even in the absence of MeCP2. This is similar to previous models of ChIP-seq (36); even best ChIP-seq libraries can have a significant level of noise ( ]^ close to 1) (37) . We also add CG-and length bias (SI Section 5.1), and process simulated reads in the same way as the experimental ChIP data.
For each ChIP-seq data set we fitted the simulated profile (parametrized by , ]^) to the experimental profile. Any ≤ 0.1 gives a good fit (Fig. S5D) , indicating that ≈ 0.1 is the upper bound on mCG occupancy in 11x OE. We used best-fit parameters to predict profiles on features other than mCG (Fig. S5E,F) . See SI Methods Section 5.3 for details.
ATAC-seq footprints. ATAC-seq was analysed in a similar way to ChIP-seq, except that we used fragments' endpoints (Tn5 insertion sites) to generate accumulated counts < . We calculated the insertion profiles as
where < efgg g<Pf and < hi are the insertion counts profiles for a given cell line and KO1, . Computer model of ATAC-seq. We use the same binding model as in the ChIP-seq simulations. We assume that MeCP2 occupies 11bp (20) and that the protein is centred on an mC. We simulate the action of the Tn5 transposase by splitting the sequence into fragments in areas free of MeCP2, and we include Tn5 sequence bias, and CG-and length bias (SI Section 6). The model has three parameters: the density of MeCP2 on mCxx, the average density of insertion (cut) sites , and the GC bias . We process simulated DNA fragments in the same way as described above for the experimental data. We examined the role of the parameters on the shape and depth of the simulated footprint of MeCP2 (SI Section 6.2) and concluded that the footprint is not affected as long as the test and control samples have been processed in a similar way. To extract MeCP2 occupancy from ATAC-seq data, we fitted the model (free parameters , , and a fixed = 6.0) to experimental footprints for all four cell lines. The relationship is linear ( Fig. 2E) , with the best-fit = 0.0058 × efgg g<Pf / st . See SI Methods Section 6 for details.
Chromatin accessibility from ATAC-seq. For each gene, we calculated its mean insertion count u and selected regions ("insertion peaks") in which < > 4 u. Accessibility was defined as the sum of all insertions in the peaks divided by the "background" u:
RNA-seq data analysis. We used a subset of protein-coding genes with sufficient methylation coverage (BS-seq; ≥80% C detected as methylated, coverage ≥20), and gene bodies 1kb or longer. This resulted in 15382 genes out of the initial 17764 protein-coding genes (86%).
To obtain the slope (Fig. 1C) we fitted straight lines Log2FC = '() + to Log2FC(expression) to different ranges of '() ∈ [ F , F + Δ ], for different pairs F ∈ [0.5,1]
and Δ ∈ [1, 4] (units: 1/100bp). The maximum slope equals of the fit with the largest absolute slope to error ratio (largest | |/ € where € is the standard error of ).
In all plots of Log2FC of differential gene expression we shifted the Log2FC values so that the average Log2FC in the range of mCG density '() ∈ [1, 6] bp/100bp was zero for all samples.
This was motivated by a difficulty in determining the absolute levels of expression since we did not quantify total mRNA.
Mathematical models of gene expression.
The condensation model assumes that the fraction < of cells in which gene is actively transcribed depends on promoter openness < plotted as a function of '() . Data does not support this model (Fig. 3C ). The detachment model poses that the probability that RNA Pol II successfully terminates is = (1 − ) P ≅ VˆP , where is the number of "abort sites" on the gene, proportional to the number of MeCP2 molecules on the gene, and is the abortion probability. We show (SI Section 9) that
where ∝ is an unknown parameter identical for all cell lines, and ‚ , ƒ are MeCP2 levels in cell lines X and Y. The model is rejected (Fig. 3E) . where is the probability that an mCG is occupied by MeCP2. See SI Section 10.2 for more details. To relate this model to the mRNA-seq differential expression data we calculate Log2FC as
where ',‚ = '() ‚ , ',ƒ = '() ƒ in which ‚ , ƒ are MeCP2 occupation probabilities for cell lines X,Y. In the above expression we know all quantities except the initiation rate which we fit to the OE 11x data (SI Section 10).
The dynamical obstacles model is very similar with two exceptions: (i) Pol II always moves with the same speed (no slow sites) as long as it is not blocked by other polymerases and obstacles, (ii) obstacles bind and unbind dynamically from the methylated sites. We assume that unbinding occurs with rate 5 per obstacle, whereas binding occurs with rate 5 per unoccupied mCG. Obstacles do not bind if an mCG is already occupied by an obstacle or a polymerase. We assume that obstacles are not restricted to accessible mCGs and that their density on actively transcribed genes may be higher than obtained from ATAC-seq but still proportional to MeCP2 level. We found that = / i"FF= reproduces Log2FC data for all cell lines. See SI Methods Section 10.3 for details. Table S1: Cell lines, their MeCP2 levels, and number of replicates for each experiment (RNAseq, ATAC-seq, ChIP-seq). Table S2 : Sequences of shRNA used to make knock-downs. Table S3 : The list of antibodies used in this work. 
